May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Retinal Toxicity of Intravitreal tPA Increases Under Ischemic Conditions
Author Affiliations & Notes
  • T. Yamamoto
    Dept of Ophthalmology, Osaka University Medical School, Suita, Japan
  • M. Kamei
    Dept of Ophthalmology, Osaka University Medical School, Suita, Japan
  • P. Kunavisarut
    Dept of Ophthalmology, Osaka University Medical School, Suita, Japan
  • M. Suzuki
    Dept of Ophthalmology, Osaka University Medical School, Suita, Japan
  • Y. Tano
    Dept of Ophthalmology, Osaka University Medical School, Suita, Japan
  • Footnotes
    Commercial Relationships  T. Yamamoto, None; M. Kamei, None; P. Kunavisarut, None; M. Suzuki, None; Y. Tano, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1488. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Yamamoto, M. Kamei, P. Kunavisarut, M. Suzuki, Y. Tano; Retinal Toxicity of Intravitreal tPA Increases Under Ischemic Conditions . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1488.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

Intravitreal injection of tissue plasminogen activator (tPA) has been reported to treat several eye conditions including intraocular fibrin formation, central retinal vein occlusion (CRVO) and submacular hemorrhage, although an excessive amount of intravitreal tPA preparation is toxic to the retina. Toxicity will increase to the retina with CRVO because tPA toxicity to neural tissues increases under ischemic conditions. We, therefore, investigated tPA toxicity to the retina on a CRVO model.

 
Methods:
 

CRVO was induced in pigmented rats with rose bengal assisted laser photothrombosis. Immediately after intravenous rose bengal injection, a laser irradiated major retinal veins adjacent to the optic nerve head. One hour after CRVO induction, (3µl of BSS or tPA(0.075, 0.75 or 3µg) was intravitreally injected. As non–ischemic controls, BSS or tPA (0.75 or 3µg) was injected in untreated eyes. All eyes were enucleated at 12 hours following injection and cryosections were made after fixation. TUNEL staining was performed to evaluate apoptosis of retinal cells. The number of positive cells were counted in three fields under a microscope.

 
Results:
 

Apoptotic cells increased when 3µg of tPA was injected to non–CRVO eyes, but without statistical significance. The number of positive cells increased in a dose–dependent manner and significantly increased when 3µg of tPA was injected into CRVO eyes. When comparing the number of apoptotic cells between non–CRVO and CRVO eyes with the same treatment, ischemia induced an increase of apoptosis and there was a significant difference between eyes injected with 3µg tPA.

 
Conclusions:
 

Retinal toxicity of intravitreally injected tPA can increase in a dose dependent manner and with ischemic conditions. These results suggest that the dose of tPA should be reduced when commercially available tPA is applied intravitreally to eyes with ischemic conditions such as CRVO.  

 
Keywords: ischemia 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×